Press Releases

Clinigen Group's £225m Acquisiton of Idis Supported by £106m in Funding from Santander, Royal Bank of Scotland and HSBC

Burton-on-Trent based Clinigen Group plc, the specialty global pharmaceutical company, has acquired Idis Group Holdings Ltd to create the market leader in the ethical unlicensed supply of medicines following £106 million in funding from Santander Corporate & Commercial, Royal Bank of Scotland and HSBC. Idis has been acquired for an enterprise value of £225 million.

Burton-on-Trent based Clinigen Group plc, has acquired Idis Group Holdings Ltd to create the market leader in the ethical unlicensed supply of medicines following £106 million in funding. 

The Clinigen Group is dedicated to delivering ‘the right drug, to the right patient at the right time’. Through its complementary business units Clinigen supplies clinical trial, licensed and ethical unlicensed critical and life-saving drugs, and serves patients, the medical community and the healthcare industry. Established for 25 years, Idis supplies ethical unlicensed medicines predominantly on an exclusive basis through managed access programmes and on-demand through its general access division.

Peter George, Chief Executive Officer of Clinigen Group, said: “Our acquisition of Idis makes us the market leader in the $5+ billion ethical unlicensed medicine supply sector and strengthens our leading position in the $2 billion clinical trial supply market. The acquisition accelerates our growth and gives us a much better balanced portfolio of businesses, whilst extending our unique business model.”

Joe Duane, Relationship Director – Large Corporates, Santander Corporate & Commercial, said: “The global ethical unlicensed supply market represents a significant growth opportunity for Clinigen. As a market leader, the firm will look to shape and define the fast growing market, and we are delighted to be able to support the group in this endeavour.”

Steve North, Relationship Director – Large Corporates, HSBC said: “The acquisition of Idis is strategically compelling and a complementary fit for Clinigen’s unique business model, creating the market leader in its field. HSBC is proud to support the group as it enters its next chapter of growth.”

Steve Simpson, Director – Structured Finance, RBS Commercial & Private Banking, said: “RBS have held a relationship with Clinigen for many years and we are delighted to welcome both HSBC and Santander into the banking arrangement to further support Clinigen’s growth.”

The information contained in this press release is intended solely for journalists and should not be used by consumers to make financial decisions.

Notes to editors
For Clinigen Group plc media enquiries, please Melanie Toyne-Sewell / Jayne Crook at Instinctif Partners: Tel: +44 (0) 20 7457 2020; Clinigen@instinctif.com

For HSBC Bank plc media enquiries, please contact:
Steve Gracey             Phone: 0207 991 4118    Email: steve.gracey@hsbc.com

For RBS media enquiries, please contact: 
Karen Cooper        Phone: 01865 343 100    Email: karen.cooper@jjmarketing.co.uk

For Santander Corporate & Commercial media enquiries, please contact:
Bijal Tanna        020 7756 4189   Mobile: 07860 259 217

The Santander Corporate & Commercial press office operates from 8.00am to 6.00pm. Outside of these hours please call 0800 5877708.

Other Articles

When you’re an established business, recruiting top talent in all the areas you need can seem like a never-ending challenge.


If you’re a start-up or small business, how can you put together an attractive employee package to appeal to top talent – graduate and…


Mexico is predicted to become one of the world’s top 10 economies in the next 10 or 20 years.

Stop fraud

More than one million incidents of financial fraud occurred in the first six months of 2016, according to official figures released by…

Santander’s Head of SME International Mark Collings discusses why exporting to new global markets may provide businesses with new and…

Where Next?